XAF1 is a newly identified tumor-suppressor gene that can antagonize XIAP and sensitize cells to other cell death triggers. In this study, we utilized ZD55, a conditionally replicative adenovirus (CRAd) similar to ONYX-015 as the vector to transfer XAF1 into the tumor cells to evaluate its antitumor efficacy in vitro and in vivo. Potent and specific cytopathic effect (CPE) was observed upon infection with ZD55-XAF1 in tumor cell lines. Importantly, ZD55-XAF1 exhibited a superior suppression of tumor growth in an animal model of colorectal carcinoma in nude mice compared with Ad-XAF1 (E1-deleted replication-defective viral) and ONYX-015. Complete eradication of the established tumors was observed in four of eight mice. Our data also showed that infection with ZD55-XAF1 resulted in caspase-independent apoptosis. Although caspase-3, poly(ADP-ribose) polymerase were mildly activated in response to ZD55-XAF1 infection, pretreatment with pan-caspase inhibitor hardly influence its apoptosis-inducing activity. In summary, our study strongly suggested that ZD55-XAF1 could serve as an effective gene-virotherapy strategy and has highly potential against human cancers.
Introduction
Failure of cancer cells to undergo therapy-induced apoptosis is a common phenomenon in cancers. 1 Thus, direct transduction of proapoptotic genes such as Fas ligand, Bax or caspases into tumor cell lines, or decreasing apoptotic threshold of tumor cells by counteracting the inhibitor of apoptosis proteins (IAP) function have been recognized as promising approaches.
2,3 XIAP (X-linked IAP) is a potent member of IAP family. It inhibits caspases-3, -7 and -9 via one or more of its baculovirus inhibitory repeat domains. 4, 5 Overexpression of XIAP has been reported in the majority of cancer cell lines. 3, 6, 7 Targeting XIAP therefore may represent a promising therapeutic approach for cancers.
XAF1 (XIAP-associated factor 1) was first isolated by the yeast two-hybrid technique on the basis of its ability to bind XIAP via the zinc-finger region. It was reported to directly antagonize the anticaspase activity of XIAP or trigger a nuclear translocation of XIAP. 8 XAF1 is widely expressed in most normal tissues, but in cancer tissues, its expression is very low or undetectable. [9] [10] [11] Recently, it was demonstrated that CpG dinucleotides upstream of the XAF1 start codon were differentially methylated in human gastric and colonic tumors, 9, 12, 13 further implicating that XAF1 acts as a tumor-suppressor gene.
Overexpression of XAF1 does not appear to induce apoptosis, 8 while previous studies have shown that overexpression of XAF1 could sensitize cancer cells to the proapoptotic effects of etoposide and tumour-necrosis factor-related apoptosis-inducing ligand (TRAIL). 8, 14 Recently, it was reported that XAF1 can cooperate with tumor necrosis factor a (TNFa) in the induction of apoptosis. 15 These studies suggest that combining XAF1 with other cell death triggers might make a preferable choice for gene therapy. However, the efficacy of such an approach and the underlying mechanisms need to be fully clarified.
Conventional gene delivery systems have some disadvantages such as poor gene transfection efficiency, low anticancer gene expression, and nontargeting to tumor cells in vivo. [16] [17] [18] In this study, we employed a conditionally replicative adenovirus (CRAd) to transfer XAF1 into the tumor cells. We inserted HA-XAF1 gene expressing cassette into ZD55, a new E1B-55-kD-deleted adenovirus, and constructed a replication-selective, transgene-expressing adenovirus ZD55-XAF1. The oncolysis capability mediated by this novel strategy was studied in human cancer cell lines and in nude mice. Our data demonstrated that ZD55-XAF1 could serve as an effective gene-virotherapy strategy against human cancers. ) were resuspended in 500 ml of binding buffer and stained with fluorescein isothiocyanate (FITC)-labeled Annexin V (BioVision, Palo Alto, CA) according to the manufacturer's instructions. A fluorescence-activated cell-sorting (FACS) assay was performed immediately after staining.
Materials and methods

Cell lines and culture conditions
Electron microscopy
Cells were trypsinized and rinsed with phosphate-buffered saline (PBS), then fixed with 5% glutaraldehyde at 41C, rinsed with PBS and post-fixed in 2% aqueous osmium tetroxide for 30 min. After washing with PBS, the samples were dehydrated through graded ethanol concentrations and Cells were embedded in Epon812 medium and were placed in 601C for 48 h. Sections were cut with an Ultracut R (Leica, Austria), double-stained with uranyl acetate and lead citrate, and examined with transmission electron microscope.
DNA fragmentation analysis
The isolation of DNA fragments was performed according to NP-40 lysis method. 19 Xenograft tumor model in nude mice animals Male BALB/c nude mice at 4-5 weeks old were obtained from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China). The SW620 cells were grown to subconfluency in complete medium. Viable cells (2 Â 10 6 in PBS) were injected subcutaneously (s.c.) into the right flank of male nude mice. When tumors reached 100-150 mm 3 , mice were divided randomly into four groups (8 mice/group) and were treated by intratumor injection of Ad-XAF1, ONYX-015, ZD55-XAF1 at totally 2 Â 10 9 plagueforming units (PFU) per animal or PBS as a control. The tumor was monitored every week by measuring tumor size using caliper for 54 days. The tumor volume was calculated by the following formula: V ¼ length Â width 2 Â 0.5. All procedures were performed according to institutional guidelines and conformed to the National Institutes of Health guidelines on the ethical use of animals.
Immunohistochemistry
Deparaffinized tumor sections were treated with 3% H 2 O 2 , blocked with SuperBlock (Scytex Laboratories, Logan, UT), and reacted treated with mouse monoclonal anti-HA (diluted 1:100) or anti-E1A (diluted 1:100) individually. After incubation with an anti-mouse secondary antibody, expression of HA-XAF1 and E1A in cells was detected with diaminobenzidine (DAB; Sigma, St Louis, MO) by enhancement with an avidin-biotin reaction ABC kit (Vector Laboratories, Burlingame, CA). The slides were then counterstained with hematoxylin.
Terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling assay Apoptotic cells in tumor specimens were detected using an in situ cell apoptosis detection kit (Sino-American Biotech Co., China) according to the manufacturer's instruction, which has been described previously. 20 
Statistical analysis
Differences among the treatment groups were assessed by the independent samples t-test and the one-way analysis of variance (ANOVA). P-values o0.05 were regarded as statistically significant.
Results
Characterization of the oncolytic ZD55-XAF1 adenovirus ZD55-XAF1 was constructed by inserting the HA-XAF1 gene expression cassette into ZD55, which was an E1B-55-kD-deleted CRAd similar to ONYX-015. To characterize this new adenovirus, we infected SW620 colon cancer cells with ZD55-XAF1, Ad-XAF1 (E1-deleted replication-defective viral), ONYX-015 or wild-type Ad5 and examined the expression of E1A and E1B-55-kD. Consistent with reported data, 21 ZD55-XAF1 expressed E1A but failed to express E1B-55-kD as did ONYX-015. Ad-XAF1 did not express either of them. In contrast, wild-type adenovirus 5 expressed both proteins ( Figure 1a ).
ONYX-015 was engineered not to express the E1B-55-kD and hence could preferentially replicate in tumor cells but not in normal cells. To determine whether E1B-55-kD deleted ZD55-XAF1 has tumor-selective replication ability, tumor cell lines (SW620, A549) and normal cells (NHLF, HSMC) were infected, respectively, with ZD55-XAF1, ONYX-015 or Ad-XAF1. The accumulation of viral particles in culture medium and cell fraction was determined by plaque assay on 293 cells. As shown in Figure 1b , ZD55-XAF1 replicated at levels comparable to ONYX-015, both of which showed much stronger replication ability in tumor cells than in normal cells. Consistently, Ad-XAF1 did not replicate in either normal cells or tumor cells. These results confirmed that ZD55-XAF1 could selectively replicate in tumor cell lines and that insertion of XAF1 did not attenuate the replication ability of the virus.
Endogenous expression of XAF1 was absent in SW620 and A549. 6 To examine exogenous XAF1 expression after infecting with ZD55-XAF1, we infected SW620, A549, HSMC and NHLF with ZD55-XAF1 at multiplicity of infection (MOI) 1 for 48 h. The cells were then harvested and subjected to Western blot assay by anti-HA antibody. As shown in Figure 1c , strong XAF1 expression was Figure 1 Characterization of ZD55-XAF1 (a) SW620 cells were mock infected or infected with Ad-XAF1, ONYX-015, ZD55-XAF1 or Ad-WT at MOI 10 for 48 h. Cell lysates were subjected to Western blot assay with anti-E1A or anti-E1B-55-kD antibody. Actin was used as a loading control. (b) Tumor cells (SW620, A549) and normal cells (NHLF, HSMC) were infected with ZD55-XAF1, Ad-XAF1 or ONYX-015. After 48 h, medium and cells were collected and subjected to three freeze-thaw cycles. The collected supernatants were tested for virus production by standard plaque assay on 293 cells. Similar results were obtained in three independent experiments. (c) Two cancer cells (SW620, A549) and two normal cells (NHLF, HSMC) were infected with ZD55-XAF1 or untreated. Expression of XAF1 was analyzed by anti-HA antibody 48 h later. Actin was used as a loading control.
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Potent cytopathic effect induced by ZD55-XAF1
Previous study suggested that overexpression of XAF1 did not appear to induce apoptosis but sensitized cells to additional cell death triggers. 8 To explore whether XAF1 could sensitize tumor cells to ZD55-triggered death, SW620, A549, NHLF and HSMC were infected with Ad-XAF1, ZD55-EGFP, ZD55-XAF1 or ONYX-015 at various MOIs as indicated. Cells were stained with crystal violet 7 days later. As shown in Figure 2a , marked cytopathic effect (CPE) was observed in both tumor cell lines infected with ZD55-XAF1 even at very low MOI (0.1-1), as compared with cells infected with ZD55-EGFP or Ad-XAF1. The CPE of ZD55-XAF1 was more than 10 times greater than that of ZD55-EGFP and about 1000-fold greater than that of Ad-XAF1 (CPE could be detected only at MOI 100) in tumor cells. The CPE of ONYX-015 was comparable to that of ZD55-EGFP. It was notable that significant suppression of cell proliferation was not observed in NHLF and HSMC for all these viruses. Similar results were obtained from several other tumor cell lines (BEL7404, Bcap37, HeLa and HepG2) while SW620 and A549 showed the greatest sensitivity to ZD55-XAF1 among them (data not shown). These results indicated that ZD55-XAF1 had selective CPE in tumor cells and inhibited the growth of tumor cells more effectively than Ad-XAF1 gene therapy or ZD55-EGFP virus therapy alone.
MTT assay was also performed to examine this result quantitatively. SW620 cells were plated in 96-well plates and infected with Ad-XAF1, ONYX-015 or ZD55-XAF1 at different MOIs as indicated. As shown in Figure 2b , infection SW620 with ZD-XAF1 resulted in a time-and dose-dependent CPE, and as was expected, ZD55-XAF1 could kill SW620 cancer cells more powerfully than Ad-XAF1 or ONYX-015 (Figure 2b ). These results indicated that XAF1 strongly potentiated ZD55-induced cell death and significant CPE could be achieved by combining XAF1 with ZD55.
ZD55-XAF1-induced caspase-independent apoptosis ZD55-XAF1 had powerful CPE on tumor cell lines. Did apoptosis play a role in this effect? To answer this question, ZD55-XAF1-induced changes were examined in terms of several parameters of apoptosis.
Cell morphology was studied by electron microscopy. SW620 cells were infected with ZD55-XAF1 at MOI 10. As shown in Figure 3A , untreated tumor cells (a) have an intact membrane, organelles and normal nuclear morphology. In contrast, cells treated with ZD55-XAF1 showed typical morphology of apoptosis, characterized by intact membranes and homogeneous condensation and margination of chromatin to the periphery of the nuclei (b). Adenovirus particles could be seen extensively in the ZD55-XAF1 infected cells, indicating that virus replicated widely in SW620 cells (c).
DNA fragmentation assays were also performed. Consistent with previous report that CRAd-induced oncolysis was not associated with apoptotic DNA fragmentation, 22 ONYX-015 and ZD55-EGFP could not induce DNA fragmentation in SW620 cells. However, obvious DNA ladder was observed in ZD55-XAF1-treated cells (Figure 3B ), indicating that XAF1 played a crucial role in this effect. Taken together, our results demonstrated that ZD55-XAF1-induced CPE was mediated at least partially by apoptosis.
As caspases (cysteine proteases) are key executors of apoptosis, we further detected whether ZD55-XAF1 employed this basic apoptotic machinery of host cell to induce apoptosis. SW620 cells were infected with ZD55-XAF1 in time-or dose-dependent manner and Western blot assay was performed to evaluate the expression of Potent Antitumor Efficacy of ZD55-XAF1 R Qi et al caspase-3 and PARP (a cellular substrate of caspase-3). Casapse-3 is an effector caspase for both extrinsic and intrinsic apoptosis pathway. 2 As shown in Figure 4A and B, very mild attenuation of procaspase-3 and PARP cleavage were observed, so it was ambiguous whether caspases were indispensable for ZD55-XAF1-mediated apoptosis.
TRAIL is member of TNF superfamily that induces apoptosis through activation of caspase-3, -8, -9; 23 previous study also showed ZD55-TRAIL could induce potent caspase activity. 20 To further verify the role of caspases in ZD55-XAF1-induced apoptosis, we compared the expression of procaspase-3 after infecting SW620 cells with ZD55-XAF1 or ZD55-TRAIL at MOI 20 for 72 h when both cell lines exhibited dramatical cell death. Figure 4C showed that infection of cells with ZD55-TRAIL resulted in marked attenuation of procaspase-3, while no noticeable effect was observed upon ZD55-XAF1 infection. In addition, pretreatment of SW620 with the pan-caspase inhibitor Z-VAD-fmk potently inhibited cleavage of procaspase-3 in ZD55-TRAIL-treated cells, and no obvious difference was seen in ZD55-XAF1-infected cells ( Figure 4C) .
As shown by Annexin V binding assay in Figure 4D , 21.65% of ZD55-XAF1-treated cells and 28.08% of ZD55-TRAIL-infected cells were apoptotic. Statistical analysis showed that pretreatment with Z-VAD-fmk had no obvious effects on ZD55-XAF1-induced apoptosis (17.66%), but significantly inhibited ZD55-TRAIL-induced apoptosis (7.53%). The lack of effect of caspase inhibition by Z-VAD-fmk on cell death triggered by ZD55-XAF1 was also observed in A549 (data not shown). Taken together, our results suggested that unlike ZD55-TRAIL, ZD55-XAF1-induced apoptosis was caspaseindependent.
In addition, it was of note that A549 tumor cells infected with ZD55-TRAIL at the same MOI always exhibited cell death characteristic about 24-48 h earlier than ZD55-XAF1 ( Figure 4E ). The process of caspaseindependent cell death is reported to be much slower than the process of caspase-dependent cell death. 24, 25 Moreover, other than cell shrinkage on infection with ZD55-TRAIL (typical apoptotic changes), cells treated with ZD55-XAF1 displayed obvious cell swelling ( Figure 4E ). These phenomena suggested that different pathways might have been utilized by ZD55-XAF1 (caspaseindependent) and ZD55-TRAIL (caspase-dependent) to induce CPE.
Antitumor efficacy of ZD55-XAF1 in nude mice
Given the promising results of ZD55-XAF1 from above study in vitro, we investigated its antitumor efficacy in vivo. SW620 s.c. tumors were established in nude mice as described. Tumors with a volume of 100-150 mm 3 were injected intratumorally with PBS, Ad-XAF1, ONYX-015 or ZD55-XAF1 every other day for a total of four injections. As shown in Figure 5A , animals treated with ZD55-XAF1 exhibited statistically significant slower tumor development compared to PBS group (Po0.003). Tumors in ZD55-XAF1-treated mice began to regress about a week after administration and by day 19, the mean tumor volume was the smallest. Complete eradication of established tumors was seen in six of eight mice, although in two of them the tumors recurred later. Administration of Ad-XAF1 resulted in a minor antitumor effect compared with ONYX-015, and no tumor regression but slower growth than PBS group was observed in these two groups.
Immunohistochemical analysis of the tumor tissues revealed strong XAF1 expression in tumor tissues 4 days after treatment with ZD55-XAF1 ( Figure 5B ). Tumor sections of ONYX-015 and ZD55-XAF1 groups stained positively for Adv E1A protein, indicating that both of them could effectively spread throughout the tumor.
Tumor sections were further analyzed for apoptosis by terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling (TUNEL) staining. As shown in Figure 5C , tumors from mice treated with ZD55-XAF1 demonstrated more extensive apoptosis compared with ONYX-015, little apoptosis was observed in Ad-XAF1 and control groups.
These results demonstrated that the therapeutic effect of ZD55-XAF1 was due to the apoptotic effect of expressed XAF1 as well as to the oncolytic effect of virus replication. (original magnification Â 5000) (B) DNA fragmentation assays. SW620 cells were infected with ONYX-015, ZD55-EGFP or ZD55-XAF1 at MOI 10 for 48 h. DNA fragmentation assays were performed as described.
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Discussion
Several important findings have been obtained from our current study in terms of using viral mediated XAF1 transfer as a gene-virotherapy approach.
Firstly, ZD55 is an efficient gene delivery vector. As a CRAd, ZD55 overcomes the shortcomings of conventional gene delivery system in that it replicates and spreads throughout the tumor tissue, thereby delivers a high dose of a therapeutic gene product efficiently and Secondly, we observed an extremely potent antitumor efficacy of combining XAF1 gene with ZD55 oncolytic virus. The CPE of ZD55-XAF1 was more than 10 times greater than that of ONYX-015 and about 1000 times 
Potent Antitumor Efficacy of ZD55-XAF1
R Qi et al greater than that of Ad-XAF1 in tumor cells. These results suggest that XAF1 sensitizes tumor cells to ZD55-induced apoptosis in vitro. The antitumor effect of ZD55-XAF1 was not observed in normal cell lines (NHLF and HSMC), indicating that ZD55-XAF1 could selectively target tumor cells. This feature is a much desired characteristic for a better gene delivery. Importantly, ZD55-XAF1 exhibited much superior suppression of tumor development comparing with Ad-XAF1 and ONYX-015 in animal experiment ( Figure 5A ). Complete eradication of the established tumors was observed in four of eight mice. Thirdly, the antitumor effect of ZD55-XAF1 was at least partially attributable to ZD55-XAF1-induced apoptosis in tumor cells, as indicated by several complementary approaches of apoptosis detection. Further, the apoptotic cell death induced by ZD55-XAF1 was caspase-independent. Very mild attenuation of procaspase-3 and P85 cleaved from PARP was observed upon ZD55-XAF1 infection even if the cells had shown dramatical CPE. As shown in Figure 4C , there was no clear indication of caspase-3 attenuation in cells treated with ZD55-XAF1 in contrast to ZD55-TRAIL that was used as a positive control for caspase-dependent apoptosis. Statistic analysis showed that pan-caspase inhibitor Z-VAD-fmk significantly inhibited ZD55-TRAIL-induced apoptosis, while had no obvious effect for ZD55-XAF1 infected cells. This is somewhat inconsistent with previous studies in that XAF1 was demonstrated to increase the activity of both caspase-3 and -9 in tumor cell lines. 26 As caspase-3 is one of the most important executioner caspases in apoptotic pathways (both internal and external), this finding may indicate that other mechanisms may be responsible for ZD55-XAF1-induced apoptosis in the cell lines tested in our study.
Caspase activation has been frequently viewed as indispensable for apoptosis. However, accumulating evidence showed that there existing other types of PCD in which caspases are not activated despite the presence of apoptotic features, such as DNA fragmentation and chromatin condensation; this type of cell death is named apoptosis-like programmed cell death. 27 Several other proteases have been described to be able to execute cell death, including calpains, cathepsins B, D, L, Omi/HtrA2 and granzymes A, B etc. They can also trigger cell death in a caspase-independent manner and bring about many of the morphological changes that are not fully consistent with classical apoptosis.
27-29 ZD55-XAF1-induced apoptosis was characterized by DNA fragmentation, chromatin condensation and PS externalization, while no obvious caspase activation was observed, so it could be categorized into apoptosis-like programmed cell death. As some tumor cells can unexpectedly survive the activation of caspases, caspase-independent cell death pathways are gaining increasing interest among cancer researchers for the design of new therapeutic strategies for cancer therapy. Although the mechanism underlying ZD55-XAF1-induced caspase-independent cell death is poorly understood until now, it is clear that it could provide new means to combat cancer.
Our study implied that ZD55-XAF1 could serve as a promising gene-virotherapy strategy for cancer treatment. However, adenoviral vectors are also limited by their highly immunogenicity which may stimulate immune rejection of the transduced cells, and resulted in short duration of transgene expression and virus replication. In clinic trails, tumor-specific replication of ONYX-015 was generally transient (o10 days). 30 Many measures have been taken to construct safer viral vectors for gene delivery. For instance, transductional targeting (e.g., through genetic modification of the viral capsid [31] [32] [33] ) or transcriptional targeting (e.g., using tumor-selective promoters to control foreign gene expression) may offer additional safety features in regulating the long-term expression. Gutless, the third generation adenovirus, lacks all viral coding regions and consequently exhibit low toxicity and immunogenicity, thus permitting prolonged expression of the transgene. 34, 35 The limitation of animal model is another broad problem to be solved for adenovirus cancer research. Owing to the poor replication of human adenovirus in other species, only immunodeficient murine models have been employed to study oncolytic potency in xenografted human tumors. 34 In an attempt to find a good murine model for CRAds, many murine cells were studied for the replication of adenovirus and several cell lines (B9, SN161, CMT-93, CMT-64) were shown to produce progeny, 36, 37 which opens the possibility to study and modulate the immune system in response to virotherapy in immune-competent animal model. In summary, the CRAd vector ZD55-mediated transfer of tumor-suppressor gene XAF1 displayed specific and remarkably potent antitumor efficacy in several tumor cells and xenografed solid tumors. Although antitumor mechanism of XAF1 has to be further elucidated for future use, our preliminary data indicate that ZD55-XAF1 is a promising gene-virotherapy strategy for cancer management.
